A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Dec 2023 Results assessing an updated analysis to indirectly compare the long-term efficacy between zanubrutinib (median follow up: 35.3 months) and orelabrutinib (median follow up: 23.8 months) in patients with R/R MCL, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
08 Jul 2023 Results (NCT03206970 and NCT03494179) assessing Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma published in the Investigational New Drugs.
02 Jun 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com